David J. Matthews - Concepedia

Author

David J. Matthews

Also Known As

D J Matthews, D. J. Matthews, D. Matthews, D.J. Matthews, DJ Matthews, David J Matthews, David J. Matthews, David Matthews, M. Krssak, Matthews, DJ

153

Publications

5.6K

Citations

H-Index

109

Concepts

All Affiliations

LifeArc Exelixis (United States)Medicines for Malaria Venture University of Washington Sunesis (United States)

About

David J. Matthews is an author at LifeArc specializing in medicine, natural sciences, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	25	2.8K
2	Natural Sciences	13	13	1.1K
3	Biochemistry	12	13	1.1K
4	Engineering	6	6	244
5	Allergy	1	1	11

David J. Matthews

Publications

4.9K

Citations

H-Index

Page 1

	Year	Citations
Efficiency of signalling through cytokine receptors depends critically on receptor orientation Rashid Syed, Scott W. Reid, Cuiwei Li, Nature InflammationCytokineMolecular PhysiologySignal TransductionFunctional Selectivity	1998	551
T1/St2-Deficient Mice Demonstrate the Importance of T1/St2 in Developing Primary T Helper Cell Type 2 Responses Michael J. Townsend, Padraic G. Fallon, David J. Matthews, The Journal of Experimental Medicine Lymphocyte DevelopmentAdaptive Immune SystemT-regulatory CellImmunologyImmunologic Mechanism	2000	470
Substrate Phage: Selection of Protease Substrates by Monovalent Phage Display David J. Matthews, James A. Wells Science BacteriophageProteasomeMolecular BiologyProtein PurificationProtein Folding	1993	340
IL-9-Deficient Mice Establish Fundamental Roles for IL-9 in Pulmonary Mastocytosis and Goblet Cell Hyperplasia but Not T Cell Development Michael J. Townsend, Padraic G. Fallon, David J. Matthews, Immunity InflammationT Cell DevelopmentInflammatory Lung DiseaseLung InflammationImmune Cell Development	2000	328
Structure-Guided Lead Optimization of Triazolopyrimidine-Ring Substituents Identifies Potent<i>Plasmodium falciparum</i>Dihydroorotate Dehydrogenase Inhibitors with Clinical Candidate Potential José M. Coterón, María Marco, Jorge Esquivias, Journal of Medicinal Chemistry	2011	280
Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target Yongyuth Yuthavong, Bongkoch Tarnchompoo, Tirayut Vilaivan, Proceedings of the National Academy of Sciences Bioorganic ChemistryAldo-keto ReductaseAntiparasitic AgentMalariaPlasmodium Falciparum	2012	274
Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13 Anup Aggarwal, Maloy Kumar Parai, N.D. Shetty, Cell	2017	180
Lead Optimization of Aryl and Aralkyl Amine-Based Triazolopyrimidine Inhibitors of<i>Plasmodium falciparum</i>Dihydroorotate Dehydrogenase with Antimalarial Activity in Mice Ramesh Gujjar, Farah El Mazouni, Karen L. White, Journal of Medicinal Chemistry	2011	165
IL-13 Is a Susceptibility Factor for <i>Leishmania major</i> Infection David J. Matthews, Claire Emson, Grahame J. McKenzie, The Journal of Immunology	2000	155
Pharmacological Abrogation of S-Phase Checkpoint Enhances the Anti-Tumor Activity of Gemcitabine In Vivo David J. Matthews, Michael Yakes, Jason Chen, Cell Cycle	2007	133

Page 1